Jtt-251 (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
86 | Pulmonary arterial hypertension | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03789643 (ClinicalTrials.gov) | March 2019 | 26/12/2018 | Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JTT-251 Administered for 24 Weeks to Participants With Pulmonary Arterial Hypertension (RELIEF-PAH) | Pulmonary Arterial Hypertension | Drug: JTT-251;Drug: Placebo | Akros Pharma Inc. | NULL | Withdrawn | 18 Years | 80 Years | All | 0 | Phase 2 | NULL |